Synlogic Inc and Ginkgo Bioworks Inc to Discuss Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines Conference Call Transcript
Good morning, and welcome to Synlogic's conference call to discuss this morning's announcement of its collaboration with Ginkgo Bioworks. (Operator Instructions) Please be advised this call is being recorded at Synlogic's request. I would now like to turn the call over to Dr. Elizabeth Wolffe, Head of Investor Relations and Corporate Communications. You may begin.
Thank you, Sarah, and good morning, everybody. This morning, we issued a press release outlining a new agreement we've established with Ginkgo Bioworks. That press release can be found on the Investors + Media section of our website. As we talk through the terms and structure of this agreement in more detail, I'd like to take a moment to point you to Slides 6 and 7 in our corporate presentation, which can also be found on the website.
Joining me on the call today is Aoife Brennan, Synlogic's President and Chief Executive Officer; and Todd Shegog, Synlogic's Chief Financial Officer; as well as Dr. Jason Kelly, Co
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |